Purpose: The goal of this work is to produce a surface-dosimetry method capable of accurately and remotely measuring skin dose for patients undergoing total skin electron therapy (TSET) without the need for postexposure dosimeter processing. A rapid and wireless surface-dosimetry system was developed to improve clinical workflow. Scintillator-surface dosimetry was conducted on patients undergoing TSET by imaging scintillator targets with an intensified camera during TSET delivery.
Methods And Materials: Disc-shaped scintillator targets were attached to the skin surface of patients undergoing TSET and imaged with an intensified, time-gated, and linear accelerator-synchronized camera. Optically stimulated luminescence dosimeters (OSLDs) were placed directly adjacent to scintillators at several dosimetry sites to serve as an absolute dose reference. Real-time image-processing methods were used to produce background-subtracted intensity maps of Cherenkov and scintillation emission. Rapid conversion of scintillator-light output to dose was achieved by using a custom fitting algorithm and calibration factor. Surface doses measured by scintillators were compared with those from OSLDs.
Results: Absolute surface-dose measurements for 99 dosimetry sites were evaluated. According to paired OSLD estimates, scintillator dosimeters were able to report dose with <3% difference in 88 of 99 observed dosimetry sites and <5% difference in 98 of 99 observed dosimetry sites. Fitting a linear regression to dose data reported by scintillator versus OSLD, per dosimetry site, yielded an R = 0.94.
Conclusions: Scintillators were able to report dose within <3% accuracy of OSLDs. Imaging of calibrated scintillator targets via an intensified, linear accelerator-synchronized camera provides rapid absolute surface-dosimetry measurements for patients treated with TSET. This technique has the potential to reduce the amount of time and effort necessary to conduct full-body dosimetry and can be adopted for use in any surface-dosimetry setting where the region of interest is observable throughout treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642820 | PMC |
http://dx.doi.org/10.1016/j.ijrobp.2018.10.030 | DOI Listing |
Spine (Phila Pa 1976)
January 2025
Indiana Spine Group Location of investigation Indiana Spine Group, 13225 N. Meridian Street, Carmel, IN 46032.
Study Design: Retrospective cohort.
Objective: To compare the clinical outcomes of trial versus standard clinical practice (SCP) patients following cervical disc arthroplasty (CDA).
Background: CDA is hypothesized to reduce the shear strain and related complications resulting from fusion procedures.
Clin Exp Optom
January 2025
Department of Ophthalmology, Dünyagöz Tunus Hospital, Ankara, Türkiye.
Clinical Relevance: Pseudoexfoliation syndrome (PXS) is a common age-related disorder associated with glaucoma and cataract. Despite its clinical importance, the pathogenesis of PXS is not yet fully understood.
Background: To evaluate levels of SCUBE-1 (signal peptide, CUB domain, and epidermal growth factor-like domain containing protein 1) in the serum and aqueous humour of patients with PXS in comparison with non-PXS controls.
Background And Aims: A catheter-related bloodstream infection (CRBSI) is a life-threatening complication of hemodialysis. It is responsible for significant morbidity and mortality and a costly long hospital stay. Despite its burden, little is known about the factors associated with it and the antibiogram of its responsible causative bacteria.
View Article and Find Full Text PDFJ Pain Res
January 2025
Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Purpose: This observational cohort study aimed to identify predictive factors associated with pain-related quality of recovery among patients undergoing elective gastrointestinal and hepato-pancreato-biliary surgery.
Patients And Methods: This study involved a secondary analysis of the data collected from five hospitals across all healthcare regions in Norway to validate the Norwegian version of the Quality of Recovery-15 (QoR-15NO). The sample consisted of 268 adult patients who underwent elective gastrointestinal and hepato-pancreato-biliary surgery between September 2021 and May 2022.
J Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!